Bayer’s Pipeline Wins Can’t Break the Chart’s Grip

The tension between Bayer’s improving fundamentals and its deteriorating stock price has rarely been sharper. On Thursday, the shares inched up just over one percent to €34.92, but the move did little to alter a technical picture that remains firmly bearish. The stock continues to trade below its 200-day moving average of €35.76, a level that technicians view as the first hurdle in any genuine recovery attempt. That line, along with the 50-day average at €38.42 and the 100-day average at €40.58, all sit above the current price—a configuration that typically signals further downside risk.

The relative strength index, which had fallen to 33.0 earlier in the week and signaled oversold conditions, has since edged up to 35.9 on a 14-day basis. That still implies weak momentum, and no clear exhaustion pattern has emerged. Without a decisive turn higher from this zone, the day’s gain looks more like a counter-trend bounce within an intact correction than the start of a sustainable rally. Over the past seven sessions Bayer has shed 7.69%, and the 30-day decline stands at 7.72%. Since the start of the year the stock is down 8.17%, a far cry from the 37% advance it still holds over the trailing twelve months.

Yet while the chart suggests caution, the company has been delivering tangible operational progress that the market appears to be ignoring. The U.S. Food and Drug Administration has granted accelerated review status to three of Bayer’s pharmaceutical candidates: the anticoagulant Asundexian, the kidney drug Kerendia, and Sevabertinib for a specific form of lung cancer. These designations do not guarantee commercial success, but they underscore the pipeline’s vitality at a time when investor sentiment is dominated by legal overhang. Separately, Bayer has moved to strengthen its ophthalmology portfolio through the planned acquisition of Perfuse Therapeutics, a deal that builds on existing core competencies rather than diversifying into unfamiliar territory.

Should investors sell immediately? Or is it worth buying Bayer?

Management has also reinforced its financial leadership. Judith Hartmann took over as chief financial officer on June 1, 2026, and her appointment signals a renewed focus on capital discipline and balance-sheet rigor. The company, which carries a market capitalisation of roughly €34.5 billion, has reaffirmed its currency-adjusted group guidance for the full year and reported a solid start to 2026, helped by a strong performance from the Crop Science division. At the same time, Reuters has reported that Bayer has no intention of breaking itself up, even as legal pressures from the Roundup glyphosate litigation persist.

The stock’s resistance levels are clearly defined. The first meaningful barrier is the 200-day line at €35.76. A clean break above that would shift the technical bias to neutral. Only above €38.42—the 50-day average—would the short-term trend brighten noticeably. On the downside, the 52-week low of €25.09 provides a distant floor, some 39% below current levels. That leaves plenty of room for further weakness before panic sets in.

For now, the market continues to price in a hefty discount for the Roundup-related legal risks that have dogged Bayer for years. Every positive development—whether from the pipeline, the new CFO, or the reaffirmed guidance—gets weighed against that liability. The range around €34 has served as a technical support zone; if it holds, the current level could offer a compelling entry point for patient investors willing to look past the noise. The pipeline advances, in particular, add genuine fundamental substance that the stock’s depressed valuation has yet to reflect.

Ad

Bayer Stock: New Analysis - 4 June

Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Bayer analysis...

en | DE000BAY0017 | BAYER’S | boerse | 69481965 |